Galderma's ready-to-use liquid botulinum toxin Type A received FDA approval in April 2024. Here's what medspa owners need to know about its formulation, clinical profile, and competitive positioning versus Dysport.
Yes, Relfydess received FDA approval on April 1, 2024, making it Galderma's third botulinum toxin Type A product in the U.S. market and the first ready-to-use liquid formulation cleared for aesthetic use. The approval came via the 510(k) pathway, establishing substantial equivalence to Dysport (abobotulinumtoxinA), Galderma's existing powder-reconstitution product.
What Makes Relfydess Distinct
Relfydess ships as a pre-filled, ready-to-inject liquid. Unlike Dysport and Botox (onabotulinumtoxinA), which require reconstitution with sterile saline, Relfydess eliminates the mixing step entirely. The formulation uses a proprietary stabilizer package designed to maintain potency without refrigeration, allowing room-temperature storage—a logistical advantage for practices managing inventory and reducing cold-chain dependency.
The active ingredient is abobotulinumtoxinA, the same neurotoxin complex as Dysport. However, Relfydess's liquid formulation may alter diffusion kinetics compared to Dysport's reconstituted powder. Early clinical data suggest a slightly faster onset (potentially 3–4 days versus 5–7 for Dysport) and comparable duration (12–16 weeks), though individual variation remains substantial.
Dosing and Unit Equivalence
Relfydess is dosed in units identical to Dysport—not 1:1 equivalent to Botox units. A typical forehead treatment with Relfydess ranges 20–25 units, similar to Dysport dosing. Practices already familiar with Dysport's diffusion profile and unit requirements will find the transition straightforward; the main operational change is eliminating reconstitution.
Regulatory and Clinical Context
Relfydess received FDA approval April 1, 2024—the first ready-to-use liquid botulinum toxin Type A, eliminating reconstitution and enabling room-temperature storage.
The 510(k) approval pathway means Relfydess was not required to conduct new pivotal efficacy or safety trials; instead, Galderma demonstrated bioequivalence and manufacturing consistency relative to Dysport. This is a faster, lower-cost regulatory route than a PMA (Premarket Approval), which Botox and Dysport underwent years ago. The approval does not imply superiority—only that Relfydess meets the same safety and efficacy standards as its predicate device.
Competitive and Economic Implications
For medspa owners, Relfydess enters a three-player market: Allergan Aesthetics (Botox), Galderma (Dysport and now Relfydess), and Revance (DaxibotulinumtoxinA, approved 2023). Galderma's ready-to-use format is a convenience play, potentially reducing chair-side prep time and waste from partial vials. Pricing and rebate structures through Galderma's Aspire loyalty program will be critical to adoption; practices should verify current per-unit cost and volume incentives against existing Dysport contracts.
The liquid format also reduces the risk of reconstitution errors—a subtle but real compliance and quality-control advantage in high-volume practices.
Current Status and Verification
Relfydess is FDA-cleared for glabellar lines, crow's feet, and forehead lines in adults. Practices should confirm current pricing, availability, and any state-specific restrictions with Galderma directly, as market dynamics and insurance/rebate terms evolve. The product is not yet universally stocked by all distributors; verify supply chain readiness before committing to inventory.
Frequently asked questions
When did Relfydess get FDA approval and what pathway was used?
Relfydess received FDA approval on April 1, 2024, via the 510(k) pathway, which establishes substantial equivalence to Dysport rather than requiring new pivotal trials. This faster regulatory route means Galderma demonstrated bioequivalence and manufacturing consistency to its existing predicate device.
What is the main difference between Relfydess and Dysport?
Relfydess is a ready-to-use liquid formulation that requires no reconstitution, while Dysport ships as a powder requiring mixing with sterile saline. Both contain the same active ingredient (abobotulinumtoxinA), but Relfydess's liquid format allows room-temperature storage and eliminates prep time and reconstitution errors.
How fast does Relfydess work compared to Dysport?
Relfydess may have a slightly faster onset of 3–4 days versus Dysport's typical 5–7 days, with comparable duration of 12–16 weeks for both products. Individual variation remains substantial, and the clinical significance of this difference is modest.
Are Relfydess units the same as Dysport or Botox units?
Relfydess uses the same unit measurement as Dysport, not Botox. A typical forehead treatment with Relfydess ranges 20–25 units, matching Dysport dosing, so practices already familiar with Dysport will find the transition straightforward.
What areas is Relfydess FDA approved for?
Relfydess is FDA-cleared for glabellar lines, crow's feet, and forehead lines in adults. Practices should verify current availability and any state-specific restrictions directly with Galderma.
Does Relfydess need to be refrigerated?
No, Relfydess uses a proprietary stabilizer package that maintains potency without refrigeration, allowing room-temperature storage. This reduces cold-chain dependency and simplifies inventory management compared to powder formulations.
Free weekly brief Get the free weekly brief.
The week's most important moves in medical aesthetics — distilled to a two-minute read, free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief every morning. The owners who read it never get blindsided.
Get the edge · $20/mo Join the owners who run ahead of the industry. Cancel anytime, one click.
